Late Breaking Abstract-A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients
DOI:
文献链接:
其他信息:
Z Luo, L Yang, A Yang, W Li, D Yu, W Li
2024
publications.ersnet.org
Background: TQC3721 is a novel dual phosphodiesterase (PDE) 3 and PDE4 inhibitor with balanced bronchodilator and anti-inflammatory effects, developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Objectives: The objective of this phase IIa clinical trial is to assess the safety and efficacy of TQC3721 in patients with COPD who are on a stable washing-out background therapy. Methods: A randomized, double-blind, placebo-controlled, multiple-ascending-dose study was conducted. Patients with moderate …